RTSN insider filings

Retension Pharmaceuticals, Inc. — 23 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-04. Screen RTSN transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 23 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Keller Eric L. — CHIEF EXECUTIVE OFFICER, Director31 leg · 20,800 sh · $249,600—6
BERGER FRANKLIN M — Director31 leg · 10,000 sh · $120,000—3
BERENDT MICHAEL J — Director3——5
Bisson Sabine — CHIEF OPERATING OFFICER2——4
Sweetnam Paul — CHIEF SCIENTIFIC OFFICER2——4
Olds Donald — Director3——3
Cheruvu Pavan — Director2——1
Wong Robert — VP, Chief Accounting Officer2——1
B Group, Inc. — 10% owner1———
Schecter Alison D. — Chief Medical Officer1———

+1 more insider in the window, not shown — every filing appears in the table below.

Recent insider filings — Retension Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2026-11-044Wong Robert — VP, Chief Accounting OfficerGrant/award (A): 25,000 (derivative) @ $0EDGAR
2026-11-043Wong Robert — VP, Chief Accounting OfficerHoldings only — no transactions reportedEDGAR
2026-10-224Keller Eric L. — CHIEF EXECUTIVE OFFICER, DirectorGrant/award (A): 40,884 (derivative) @ $0EDGAR
2026-10-163B Group, Inc. — 10% ownerHoldings only — no transactions reportedEDGAR
2026-10-134Cheruvu Pavan — DirectorGrant/award (A): 5,636 (derivative) @ $0EDGAR
2026-10-134Olds Donald — DirectorConversion (C): 5,637 · Conversion (C): 5,637 (derivative)EDGAR
2026-10-134Sweetnam Paul — CHIEF SCIENTIFIC OFFICERConversion (C): 4,026 · Conversion (C): 2,640 · Conversion (C): 4,026 (derivative) · Conversion (C): 2,640 (derivative)EDGAR
2026-10-134Keller Eric L. — CHIEF EXECUTIVE OFFICER, DirectorPurchase (P): 20,800 @ $12 · Conversion (C): 9,662 · Conversion (C): 31,368 · Grant/award (A): 255,174 (derivative) @ $0 · Conversion (C): 9,662 (derivative) · Conversion (C): 31,368 (derivative)EDGAR
2026-10-133Cheruvu Pavan — DirectorHoldings only — no transactions reportedEDGAR
2026-10-134BERENDT MICHAEL J — DirectorConversion (C): 4,026 · Conversion (C): 2,640 · Conversion (C): 4,026 (derivative) · Conversion (C): 2,640 (derivative)EDGAR
2026-10-134BERGER FRANKLIN M — DirectorConversion (C): 12,517 · Purchase (P): 10,000 @ $12 · Conversion (C): 12,517 (derivative)EDGAR
2026-10-134Bisson Sabine — CHIEF OPERATING OFFICERConversion (C): 1,611 · Conversion (C): 2,504 · Conversion (C): 1,611 (derivative) · Conversion (C): 2,504 (derivative)EDGAR
2026-10-084Olds Donald — DirectorGrant/award (A): 5,636 (derivative) @ $0EDGAR
2026-10-084BERENDT MICHAEL J — DirectorGrant/award (A): 5,636 (derivative) @ $0EDGAR
2026-10-084BERGER FRANKLIN M — DirectorGrant/award (A): 5,636 (derivative) @ $0EDGAR
2026-10-083Schwartz Alexander Duke — Chief Financial OfficerHoldings only — no transactions reportedEDGAR
2026-10-083Olds Donald — DirectorHoldings only — no transactions reportedEDGAR
2026-10-083Schecter Alison D. — Chief Medical OfficerHoldings only — no transactions reportedEDGAR
2026-10-083Sweetnam Paul — Chief Scientific OfficerHoldings only — no transactions reportedEDGAR
2026-10-083BERENDT MICHAEL J — DirectorHoldings only — no transactions reportedEDGAR
2026-10-083BERGER FRANKLIN M — DirectorHoldings only — no transactions reportedEDGAR
2026-10-083Bisson Sabine — Chief Operating OfficerHoldings only — no transactions reportedEDGAR
2026-10-083Keller Eric L. — Chief Executive Officer, DirectorHoldings only — no transactions reportedEDGAR

Recent 8-K events — Retension Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-188-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-238-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-138-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — Retension Pharmaceuticals, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=RTSN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs